HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ensar Halilovic Selected Research

S55746

1/2019Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ensar Halilovic Research Topics

Disease

17Neoplasms (Cancer)
03/2022 - 08/2008
5Leukemia
03/2022 - 10/2015
2Breast Neoplasms (Breast Cancer)
12/2020 - 01/2019
2Uveal melanoma
01/2020 - 06/2016
2Melanoma (Melanoma, Malignant)
01/2019 - 11/2017
2Colorectal Neoplasms (Colorectal Cancer)
12/2016 - 07/2010
1Liposarcoma
01/2022
1Disease Progression
01/2022
1Genomic Instability
01/2021
1Thrombocytopenia (Thrombopenia)
01/2021
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/2020
1Multiple Myeloma
01/2020
1Neuroendocrine Tumors (Neuroendocrine Tumor)
01/2018
1Neoplasm Metastasis (Metastasis)
11/2017
1Lung Neoplasms (Lung Cancer)
11/2008
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2008

Drug/Important Bio-Agent (IBA)

5NVP-CGM097IBA
01/2021 - 05/2015
4siremadlinIBA
03/2022 - 11/2018
4Pharmaceutical PreparationsIBA
12/2020 - 08/2010
4Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
09/2010 - 11/2008
3Biomarkers (Surrogate Marker)IBA
01/2021 - 05/2015
3S63845IBA
12/2020 - 01/2019
2Immune Checkpoint InhibitorsIBA
01/2021 - 11/2017
2venetoclaxIBA
12/2020 - 01/2020
2Proteins (Proteins, Gene)FDA Link
12/2020 - 10/2015
2Drug CombinationsIBA
01/2020 - 12/2016
2Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
01/2019 - 09/2010
2Cyclin D1IBA
01/2019 - 09/2010
2Biological ProductsIBA
11/2017 - 07/2010
2ErbB Receptors (EGF Receptor)IBA
08/2010 - 11/2008
2Phosphotransferases (Kinase)IBA
08/2010 - 11/2008
2Proto-Oncogene Proteins B-rafIBA
11/2008 - 08/2008
2Mitogen-Activated Protein KinasesIBA
11/2008 - 08/2008
1CyclinsIBA
01/2022
1ribociclibIBA
01/2022
1AntigensIBA
01/2021
1Transcription Factors (Transcription Factor)IBA
01/2021
1Blocking AntibodiesIBA
01/2021
1Growth Differentiation Factor 15IBA
01/2021
1S55746IBA
01/2019
1Cyclin-Dependent Kinases (cdk Proteins)IBA
01/2019
1Cyclin-Dependent Kinase Inhibitor p27IBA
01/2019
1Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA
01/2018
1Fluorouracil (Carac)FDA LinkGeneric
01/2018
1sotrastaurinIBA
06/2016
1MTOR InhibitorsIBA
06/2016
1Protein Kinase CIBA
06/2016
1Mechanistic Target of Rapamycin Complex 1IBA
06/2016
1EverolimusFDA Link
06/2016
1LigandsIBA
11/2012
1Phosphatidylinositols (Phosphatidylinositol)IBA
09/2010
1mirdametinibIBA
09/2010
1VemurafenibIBA
08/2010
1ras ProteinsIBA
07/2010
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
11/2008
1MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA
11/2008
1tyrosine receptor (receptor, tyrosine)IBA
11/2008

Therapy/Procedure

8Therapeutics
12/2020 - 08/2008
2Drug Therapy (Chemotherapy)
01/2019 - 12/2016
1Regimen B
01/2022
1Immunotherapy
01/2021